Use of Organs from Hepatitis C Viremic Donors: Addressing the Needs of a Changing Waitlist and the Effect of a Public Health Crisis
Welcome to the new academic journal OBM Hepatology and Gastroenterology. Recent progress in understanding liver, biliary, pancreatic and gastro-intestinal diseases and their treatments has been observed in the world. OBM Hepatology and Gastroenterology publishes interesting and informative reviews, original articles, and invaluable case reports in this area. We also publish basic research as well as clinical research.
Hepatitis A virus (HAV), HBV, HCV, HDV, and HEV are still a serious issue worldwide. Treatments on these viruses have recently improved. However, liver fibrosis, cirrhosis and hepatocellular carcinoma are still critical conditions. We focus on all of these liver diseases. We also focus on broad-spectrum of gastro-intestinal diseases in this journal.
Please accept our special thanks for choosing to publish in the OBM Hepatology and Gastroenterology. We are looking forward to your submissions for OBM Hepatology and Gastroenterology.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 6.8 days from acceptance to publication (median values for papers published in this journal in 2020, 1-2 days of FREE language polishing time is also included in this period).
Unmet Need in the Management of Chronic Hepatitis C
Submission Deadline: January 31, 2020 (Open) Submit Now
Chung-Feng Huang, MD,PhD
1. Associate Professor, Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
2. Faculty of Medicine and Hepatitis Research Center, College of Medicine, and Center for Infectious Disease, Kaohsiung Medical University, Kaohsiung, Taiwan
Research Interests: Liver Diseases; Hepatocellular Carcinoma; Chronic Hepatitis C; Viral Hepatitis
About This Topic
Hepatitis C virus (HCV) infection is one of the major etiologies of liver cirrhosis and hepatocellular carcinoma worldwide. With the great innovation of directly acting antivirals, most patients with chronic hepatitis C (CHC) could be cured. However, there are several unmet needs to be solved. For example, the gap of HCV diagnosis and accessibility to medical care, difficult-to-cure populations including patients with liver decompensation, treatment-emergent variants and retreatment options, and long-term hepatic and extrahepatic outcomes in the post sustained virologic response (SVR) era. This special section seeks submissions for including but not restricted to abovementioned hot issues. The submissions can be in the form of review articles, opinions or original research. We would like to invite you to submit your work for consideration of publication in this special issue.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.